Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Silvia Pietrobono

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5544-7286; OpenAlex author ID A5033268263. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 5 papers · 2025: none · 2026: 3 papers

Papers 9

  1. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Co-author DOI 10.1016/j.esmoop.2026.106964↗
  2. EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages. Co-author DOI 10.1038/s41388-026-03774-0↗
  3. Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-026-01442-w↗
  4. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.05.547↗
  5. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  6. CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-024-00742-3↗
  7. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-0104↗
  8. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. Co-author DOI 10.1177/17588359241234487↗
  9. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Co-author DOI 10.3389/fsurg.2022.866173↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Simona Casalino · 9 shared papers, 2022–2026 · strength 1.96
  2. Davide Melisi · 9 shared papers, 2022–2026 · strength 1.96
  3. Valeria Merz · 8 shared papers, 2022–2026 · strength 1.69
  4. Enza Scarlato · 5 shared papers, 2024–2026 · strength 1.17
  5. Giovanni Butturini · 2 shared papers, 2024–2026 · strength 0.41
  6. Roberto Salvia · 2 shared papers, 2024–2026 · strength 0.41
  7. Giuseppe Malleo · 1 shared paper, 2024 · strength 0.15
  8. Alessandro Esposito · 1 shared paper, 2024 · strength 0.15
  9. Riccardo De Robertis · 1 shared paper, 2024 · strength 0.15
  10. Mirko D’Onofrio · 1 shared paper, 2024 · strength 0.15
  11. Stefano Francesco Crinò · 1 shared paper, 2024 · strength 0.15
  12. Claudio Luchini · 1 shared paper, 2024 · strength 0.15
  13. Claudio Bassi · 1 shared paper, 2024 · strength 0.15
  14. Giovanni Marchegiani · 1 shared paper, 2024 · strength 0.15
  15. Aldo Scarpa · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.